Irritable bowel syndrome.
BACKGROUND
The prevalence of irritable bowel syndrome (IBS) varies depending on the criteria used to diagnose it, but ranges from about 5% to over 15%. IBS is associated with abnormal gastrointestinal motor function and enhanced visceral perception, as well as psychosocial and genetic factors. People with IBS have an increased likelihood of having a cholecystectomy or hysterectomy compared with people without IBS.


METHODS
We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments in people with IBS? We searched: Medline, Embase, The Cochrane Library and other important databases up to June 2006 (BMJ Clinical evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).


RESULTS
We found 23 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.


CONCLUSIONS
In this systematic review we present information relating to the effectiveness and safety of the following interventions: 5HT(3) receptor antagonists other than alosetron, 5HT(4) receptor agonists (tegaserod), alosetron, antidepressants, antispasmodics, cognitive behaviour therapy, hypnotherapy, insoluble fibre supplementation, loperamide.
de Wit
Niek
N
Julius Center for Health Sciences and Primary Care, University Medical Center, Universiteitsweg, Utrecht, The Netherlands.
Rubin
Gregory
G
Jones
Roger Hugh
RH
D043183:Irritable Bowel Syndrome; D014481:United States